Clinical trial
Safety and Tolerability of Glatiramer Acetate
NCT01874145
Study timeline
Study start (unknown)2013-06-01Date precision: month
Registry last updated2016-01-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Relapsing-Remitting Multiple Sclerosisunresolved
Interventions
GA 20 mg/mLDRUG
GA 40 mg/mLDRUG
Sponsors & collaborators
Teva Branded Pharmaceutical Products R&D, Inc.lead sponsor
Mapped research locations
TampaFlorida, United States2BaltimoreMaryland, United States1NashvilleTennessee, United States1ColumbusOhio, United States1IndianapolisIndiana, United States1PhoenixArizona, United States1Salt Lake CityUtah, United States1CharlotteNorth Carolina, United States1Winston-SalemNorth Carolina, United States1Long BeachCalifornia, United States1RaleighNorth Carolina, United States1DaytonOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01874145 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.